HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

Rare Disease Drug Approvals

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (rare disease) as Genzyme.

Regulatory Analysis

This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.

Supporting Context

Therapeutic area
Genetic Disorders · Pompe Disease
Sub-indication
Rare Disease

Related signal: Genzyme Launches Global Registry for Pompe Disease to Enhance Patient Care and Research

Source

View source document

Related Signal

Open signal — Genzyme Launches Global Registry for Pompe Disease to Enhance Patient Care and Research
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.